Oblique

22/02/2022

🎹 🎶 STUDIO À LOUER 🎶 🎹
À L'ABBAYE DE LA CAMBRE
DISPONIBLE IMMÉDIATEMENT
MP SI INTÉRESSÉ

07/01/2022

NEW. Brand identity for:
☁️ .objects ☁️

18/03/2021

NEW ⚪ logo & teaser for Circle by NORM.
Sound by

02/12/2020

NEW 💧💧💧 visual identity and packaging for
soil – cbd oil.

27/10/2020

NEW 🌚🌑🌚 Teasers for NORM's upcoming BLACK HOLE Edition
🎼 © Music by

22/06/2020

Our gradient raincoat for the Brussels tourist agency .
📷.1 by .radio

18/06/2020

Back in 2012, digital and physical campaign for the 18th anniversary of the iconic club .

@ Fuse

25/05/2020

Back in 2015, à visual identity, various documents and an application for a European institutional project aiming to alert populations and help them to cope with crisis.

-19

12/05/2020

Back in time, visual identity and various supports for blank, Christine Degraeve's colorful gallery in Brussels.



📷 Mathias Vancoppenolle

04/10/2016

Recently completed Wilfried Martens Centre for European Studies 2015 Activity Report. An overview of everything that was done during this busy year for the Political foundation at European level of the European People's Party. Great care was put into the making and presenting of the organization, publications, events, projects and projects with members foundations. The result is a 70 pages fresh, document, easy to read yet filled with loads of information.
You can download and check following this link :
http://www.martenscentre.eu/publications/activity-report-2015

10/09/2015

Congratulations to our client NOVADIP for attracting a 28 millions euros in investment for their revolutionary product CREOST. Oblique found their name, their product name and made their identity.
Article on l'ECHO (french) : http://www.lecho.be/entreprises/pharma_biotechnologie/Novadip_leve_d_emblee_28_millions_d_euros_et_attire_un_fonds_americain.9673982-3002.art

La réputation du tissu biotechnologique belge, wallon en particulier, n’était déjà plus à faire. Elle devrait être renforcée dans les années à venir par les perspectives de développement qui s’offrent à un nouvel acteur: Novadip Biosciences.